Torrent Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Torrent Pharmaceuticals (TORNTPHARM) reported revenue ₹4,111 Cr and net profit ₹364 Cr — revenue +42.2% YoY. For annual financials, live price and key ratios, visit TORNTPHARM share price screener.
TORNTPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Torrent Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Torrent Pharmaceuticals stock price data download to track price trends across different timeframes.
- Revenue of ₹4,111 Cr in Mar 2026 (+27.7% vs Sept 2025, +42.2% vs Mar 2025)
- Net Profit of ₹364 Cr in Mar 2026 (-38.4% vs Sept 2025, -26.9% vs Mar 2025)
- EBITDA of ₹1,204 Cr in Mar 2026 (+22.0% vs Sept 2025)
- Operating Margin of 30.0% in Mar 2026 (-1.0pp vs Sept 2025)
- Earnings Per Share of ₹11.51 in Mar 2026 (-34.4% vs Sept 2025)
Torrent Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TORNTPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 4,111 | 3,219 | 2,891 | 3,091 | 3,238 | 27.7% | 42.2% |
| Net Profit (₹ Cr) | 364 | 591 | 498 | 548 | 635 | - | - |
| EBITDA (₹ Cr) | 1,204 | 987 | 872 | 945 | 1,013 | - | - |
| EPS (₹) | 11.51 | 17.54 | 14.71 | 16.19 | 18.77 | - | - |
| Operating Margin (%) | 30.0% | 31.0% | 31.0% | 31.0% | 32.0% | - | - |
TORNTPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Torrent Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse TORNTPHARM annual financials for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
TORNTPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Torrent Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
|
Lupin
Mar 2026 |
₹110,051.30 Cr | 2370.5 | 7,533 | 1,469 | +8.8% | +34.1% | 19.5% | 68.1 |
All amounts in ₹ Crores